



Ashland joins University of Texas at Austin College of Pharmacy, participates in Life Science Twin Screw Extrusion Workshop

November 6, 2023

Company will share materials expertise including new Klucel Fusion™ hpc

Wilmington, Del., Nov. 6, 2023 - Ashland will join The University of Texas at Austin - College of Pharmacy and other pharmaceutical industry leaders of advanced extrusion technology at the Life Science Twin Screw Extrusion Workshop hosted by [Leistritz Advanced Technologies Corp.](#) November 8 - 9, 2023 in Austin TX. In addition to Leistritz staff, speakers from industry and academia will contribute.

Participants will learn how to process wide ranging pharmaceutical dosage forms via the continuous twin screw extrusion process. Classroom sessions will be supplemented by interactive "hands-on" extrusion system demonstrations at the UT Austin College of Pharmacy laboratories.

Continuous manufacturing via twin screw extrusion is a preferred manufacturing technology for GMP environments. Twin screw melt granulation (TSMG) is a continuous process that can eliminate the need for solvents and rate-limiting drying, thus significantly reducing energy consumption, enhancing throughput, reducing operating cost, and shortening scaleup development time by approximately 60 percent.

Kapish Karan, global OSD leader, pharmaceutical R&D, life sciences, Ashland, will speak on material selection for extrusion and Ashland will contribute materials expertise including new [Klucel Fusion™ hydroxypropyl cellulose](#) (hpc). Klucel Fusion™ hpc is a new polymer expressly designed to optimize performance in twin screw melt granulation (TSMG) for pharmaceutical manufacturers. Klucel Fusion™ hpc offers stellar tablet binding at a significantly lower melt processing temperature. It is the only purpose-designed melt granulation binder on the market.

"Ashland scientists are paving the way for these manufacturing processes and collaborating with pharma customers to improve product quality, reduce production time, enable greater flexibility, and reduce manufacturing costs while increasing process yields," said Brandt Giffin, senior director strategic marketing and new business development, life sciences, Ashland. "This will result in more sustainable solutions with fewer manufacturing steps for pharmaceutical manufacturers, and better product attributes for enhanced tablet performance for consumers."

About Ashland

Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social, and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care, and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative, and elegant solutions to complex problems for customers in more than 100 countries. Visit [ashland.com](#) and [ashland.com/ESG](#) to learn more.

™Trademark, Ashland, or its subsidiaries, registered in various countries.

FOR FURTHER INFORMATION:

Media Relations

Nancy H. Pitts

+1 (412)628-8791

nancy.pitts@ashland.com